JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
JAGUAR
1 other identifier
interventional
450
1 country
29
Brief Summary
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Sep 2021
Longer than P75 for not_applicable
29 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 18, 2021
CompletedStudy Start
First participant enrolled
September 20, 2021
CompletedFirst Posted
Study publicly available on registry
October 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2031
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 1, 2031
June 8, 2025
June 1, 2025
9.4 years
September 18, 2021
June 5, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Number of Participants with Freedom from Aneurysm-Related Complications (ARC)
Composite endpoint consisting of aneurysm-related death, aneurysm rupture, conversion to open surgery, type I and III endoleaks, device migration (\>10mm), aneurysm sac enlargement (\>5mm), occlusion, and freedom from device-related interventions
Through 5 years
Neck Dilation in mm
Through 5 years
Secondary Outcomes (18)
Number of Major Adverse Events (MAEs)
At 30 days and 12 months
Count of participants All Cause Mortality
At 30 days, 12 months, and annually up to five years
Count of participants AAA-related Mortality
At 30 days, 12 months, and annually up to five years
Number of Type Ia endoleaks
At 30 days, 12 months, and annually up to five years
Number of Type Ib
At 30 days, 12 months, and annually up to five years
- +13 more secondary outcomes
Study Arms (2)
Alto Abdominal Stent Graft System
EXPERIMENTALSubjects randomized to receive the Endologix Alto Abdominal Stent Graft System for implantation to repair Abdominal Aortic Aneurysm.
Comparators
ACTIVE COMPARATORSubjects randomized to receive the comparator AAA Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm.
Interventions
Endovascular Abdominal Aneurysm Repair (EVAR) using commercially available, FDA approved endovascular graft systems implanted.
Eligibility Criteria
You may qualify if:
- Adult age 21 and older
- Subjects with minimum of 2 year life expectancy
- Subjects have signed the informed consent document
- Subjects with unruptured infrarenal AAA who are assessed by the Investigator to be eligible for endovascular Abdominal Aortic Aneurysm Repair with the trial devices.
- Patient must be able and willing to comply with all required follow-up exams.
You may not qualify if:
- Currently participating in another trial where the primary endpoint has not been reached yet.
- Known allergy to any of the device components
- Pregnant (females of childbearing potential only)
- Known connective tissue disorders
- Known active infection
- Subjects with pre-existing EVAR, i.e., in need of repair/intervention of a previously failed EVAR.
- Patient has other medical, social, or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Endologixlead
Study Sites (29)
Huntsville Hospital
Huntsville, Alabama, 35801, United States
University of Arizona
Tucson, Arizona, 85716, United States
Washington Regional Medical Center
Fayetteville, Arkansas, 72703, United States
Central Arkansas Veterans Healthcare System
Little Rock, Arkansas, 72205, United States
The Regents of the University of California, San Diego
La Jolla, California, 92093, United States
Veterans Affairs San Diego Healthcare System
San Diego, California, 92161, United States
MedStar Washington Hospital Center
Washington D.C., District of Columbia, 20001, United States
Jacksonville Center for Clinical Research
Jacksonville, Florida, 32216, United States
Radiology and Imaging Specialists
Lakeland, Florida, 33801, United States
Baptist Hospital of Miami, Miami Cardiac and Vascular Institute
Miami, Florida, 33176, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
University of Louisville
Louisville, Kentucky, 40202-1959, United States
Tufts Medical Center
Boston, Massachusetts, 02111, United States
Henry Ford Hospital
Detroit, Michigan, 48202, United States
University of Missouri
Columbia, Missouri, 65212, United States
Newark Beth Israel Medical Center
Newark, New Jersey, 07112, United States
Icahn School of Medicine at Mount Sinai
New York, New York, 10029-6574, United States
Feinstein Institutes for Medical Research (Staten Island University Hospital/Northwell Health)
Staten Island, New York, 10305, United States
The Cleveland Clinical Foundation
Cleveland, Ohio, 44106, United States
The Ohio State University
Columbus, Ohio, 43210, United States
Oregon Health Sciences University
Portland, Oregon, 97239, United States
U.S. Department of Veterans Affairs, VA Portland Health Care System
Portland, Oregon, 97239, United States
Lehigh Valley Health Network
Allentown, Pennsylvania, 18103, United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Allegheny Health Network
Pittsburgh, Pennsylvania, 15212, United States
Wellmont Cardiology Services
Kingsport, Tennessee, 37660, United States
The University of Texas Medical Branch at Galveston
Galveston, Texas, 77555, United States
Houston Methodist Research Institute
Houston, Texas, 77030, United States
Sentara Hospitals
Norfolk, Virginia, 23507, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sean Lyden, MD
The Cleveland Clinic
- PRINCIPAL INVESTIGATOR
Christopher Kwolek, MD
Newton-Wellesley Hospital
- PRINCIPAL INVESTIGATOR
Hence Verhagen, MD, PhD
Erasmus University Study Center
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 18, 2021
First Posted
October 1, 2021
Study Start
September 20, 2021
Primary Completion (Estimated)
March 1, 2031
Study Completion (Estimated)
March 1, 2031
Last Updated
June 8, 2025
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared with others.